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Streptococcus pneumoniae is the leading bacterial cause of
paediatric community-acquired pneumonia (PCAP) (Rudan et al.,
2008). The 7-valent pneumococcal conjugate vaccine (PCV7) (sero-
types 4, 6B, 9V, 14, 18C, 19F, and 23F) was added into the UK
immunisation schedule from September 2006; subsequently replaced
by PCV13 from April 2010 (additional serotypes 1, 3, 5, 6A, 7F, and19A). Three vaccine doses are administered at the age of 2, 4, and 13
months. When the vaccine was introduced, a catch up programme
was offered to all children born between September 2004 and
September 2006. This vaccination programme would thus be
expected to impact upon the pneumococcal serotypes implicated
in PCAP.
Pathogens are difﬁcult to identify in children with pneumonia,
with blood culture and serological testing often negative due to
minimal presence of bacteremia (Brent et al., 2006; Korppi et al.,
2008). This paucity of S. pneumoniae isolation makes examining
pneumococcal serotype distribution in PCAP difﬁcult, with no UK,
and little worldwide, data. Using non-culture techniques including
pneumococcal detection by polymerase chain reaction (PCR) in
blood (Resti et al., 2010) and pleural ﬂuid (Strachan et al., 2012),
pneumococcal antigen detection in urine (Charkaluk et al., 2006),
and pneumococcal serotype detection by PCR (Esposito et al.,
2012; Resti et al., 2010), we sought to determine the contribution
of S. pneumoniae and speciﬁc serotypes to the aetiology of PCAP.
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Now as being indicative of invasive pneumococcal infection for
several reasons. It has good sensitivity (100%) and speciﬁcity (56%) in
children with suspected pneumococcal disease (Charkaluk et al.,
2006), but is confounded as a diagnostic test by nasopharyngeal
carriage where up to 21% may be positive (Hamer et al., 2002).
Urinary pneumococcal antigen may also be positive in 4% healthy
nasopharyngeal culture-negative children (Hamer et al., 2002),
although given the increased sensitivity of PCR compared to culture,
it is likely that nasopharyngeal culture-negative children would have
pneumococcal carriage if tested by PCR (Turner et al., 2011). Thus, a
positive urinary antigen in a child with pneumonia and no
pneumococcal nasopharyngeal carriage by PCR is likely to reﬂect
invasive pneumococcal disease.
2. Materials and methods
2.1. Study population
From October 2009 to March 2011 children aged ≤16 years old
with clinical and radiological features suggestive of pneumonia
admitted to any of three hospitals in North East England were
prospectively enrolled. Informed consent was obtained from parents
and assent from older children. Ethical and Caldicott approvals were
granted (Newcastle and North Tyneside Research Ethics Committee
(No: 08/H0906/105), and Research Approval Board at South Tees
Hospitals NHS Trust (No: 2008075)).
Pneumonia was deﬁned by signs and symptoms suggestive of
lower respiratory tract infection and chest radiographic ﬁndings
consistent with pneumonia as determined initially by the local
paediatrician. Exclusions included being resident outside North East
England, clinical bronchiolitis, hospitalisation in the preceding three
weeks, or normal chest radiograph after review by a radiologist. Chest
radiographs were ﬁrst reported by local radiologists then reviewed by
a second consultant cardiothoracic radiologist at the regional centre.
Radiographic ﬁndings were categorised into lobar, patchy, or perihilar
according toWorld Health Organization criteria (Cherian et al., 2005).
Conjugate pneumococcal vaccination history was ascertained.
2.2. Laboratory procedures
Blood samples were collected for serum, blood culture (BacT/
ALERT®, bioMérieux) and pneumococcal PCR testing. Nasopharyngeal
aspirates (NPA) were obtained from infants, and placed in 0.9%
sodium chloride transport solution. For older children, bacterial
nasopharyngeal swab (NPS) was collected. Expectorated sputum
and tracheobronchial secretions (TBS) (sampled via endotracheal
tube or bronchoalveolar lavage) and pleural ﬂuids were tested when
collected. Secretions were inoculated into plates of Columbia agar
(Oxoid) supplemented with 5% horse blood (CBA) and Oxoid brain-
heart infusion broth with 10% serum (Oxoid). Broths were incubatedTable 1
Laboratory investigations and diagnostic criteria of pneumococcal infection.
Sample Pathogen/antigen
Blood S. pneumoniae
Nasopharyngeal secretions, sputum S. pneumoniae
Tracheobronchial secretions
(endotracheal/bronchoalveolar lavage)
S. pneumoniae
Pleural ﬂuid S. pneumoniae
Pneumococcal antigen
Urine Pneumococcal antigen
a ELISA, enzyme-linked immunosorbent assay.overnight at 37 °C and sub-cultured (10 μL) into CBA plates for
incubation at 37°C in 5% carbon dioxide for 48 hours. Pneumococcal
isolates were identiﬁed by standard methods including latex
agglutination and API 32 STREP (bioMérieux). Urine samples were
tested for pneumococcal antigen using Binax NOW (Inverness
Medical Innovations Ltd, Ireland). Not every child had all tests
performed.
Total nucleic acid was extracted from blood, respiratory secretions,
culture-negative pleural ﬂuid, and pneumococcal antigen positive
urine samples for PCR using an EasyMag automated nucleic acid
extraction instrument (bioMérieux) and the resulting nucleic acid
used as template in a S. pneumoniae speciﬁc PCR targeting the
pneumolysin gene (and autolysin gene for pleural ﬂuids) (Corless et
al., 2001). Any recovered S. pneumoniae was serotyped using a
multiplexed xMAP immunoassay for detection of serotype-speciﬁc S.
pneumoniae antigens (Sheppard et al., 2011). This assay identiﬁes
PCV13-serotypes plus serotype 8.
2.3. Diagnostic criteria for pneumococcal infection and
statistical analysis
S. pneumoniae was considered a deﬁnite or probable pathogen
when detected from a sterile site, TBS or urine samples. Pneumococcal
detection in NPA/NPS or sputum was considered a possible pathogen
and likely to represent nasopharyngeal carriage in children (Table 1).
Detection rates of pathogens are expressed as proportions of those
tested. Fisher's exact test was used to compare different detection
methods and odds ratios and 95% conﬁdence intervals were
calculated. Data were analysed using Epi Info™ 7.
3. Results
Of 160 children, 56%weremale and 69% aged b5 years, median age
2.6 years. All received antibiotics, none died. Radiographs showed 61%
lobar consolidation, and 42.5% pleural effusion. Forty (25%) children
had empyema. Based on age, pneumococcal vaccination uptake
among 119 eligible children was 94% (89 had PCV7, 10 PCV13, and
13 received combinations of each) (online supplement). Pneumococci
were detected from any site in 64% of children (103/160). S.
pneumoniaewas identiﬁed from nasopharyngeal secretions by culture
in 7% (10/141) and by PCR in 63% (76/121); and from sterile sites in
17.4% (24/138); by culture in 6% (8/132); comparedwith PCR in 21.6%
(21/97), P = 0.0004.
S. pneumoniae was the likely (deﬁnite/probable) pathogen in 26%
(39/149); 20.8% (21/101) and 37.5% (18/48) tested among those aged
b5 and ≥5 years respectively. Of the 39 pneumococcal infections, 21
children had empyema. Pneumococcal infections among those who
received PCV7 was 26.5% (22/83), compared to 10.5% (2/19) for those
who either had PCV13 alone or doses of both (P= 0.182). A serotype
was identiﬁed in 82% tested (23/28); serotypes 1 (n= 10), 3 (n= 5),
7A/F and 19A (n = 4 each) (Table 2). Apart from two children whoTestsa Diagnosis of causative pathogens
Deﬁnite/probable Possible
Culture/real-time PCR Growth/positive –
Culture/real-time PCR – Growth/positive
Culture/real-time PCR Growth/positive –
Culture/real-time PCR Growth/positive –
ELISA Positive –
Binax NOW Positive –
Table 2
Proportions of detected pneumococci and serotype distribution.
Tests Tests, n Positive, n (%) Serotype (n/N, types)a
Overall deﬁnite/probable infections 149 39 (26.0) 23/28 1 (n = 10), 3 (n = 5), 7A/F (n = 4), 19A (n = 4)
Blood (total) 136 11 (8.0) 6/6
Culture 126 5 (4.0) 3/3 1, 3, 19A
Pneumolysin real-time PCR 86 7 (8.1) 3/3 3, 19A (n = 2)
Pleural ﬂuid (total) 40 19 (47.5) 17/19
Culture 40 3 (7.5) 3/3 1, 19A (n = 2)
Pneumococcal antigen 30 7 (23.3) 6/6 1 (n = 5), 3
Pneumolysin real-time PCR 30 18 (60.0) 18/18 1 (n = 7), 3 (n = 5), 19A (n = 4), 7A/F and NT (n = 1 each)b
Respiratory secretions (total) 151 82 (54.3) 1/10
Nasopharyngeal culture 141 10 (7.0) 5/10 23B, NT (n = 4)
Tracheobronchial culturec 12 1 (8.3) –
Pneumolysin real-time PCR 121 76 (62.8) –
Urinary pneumococcal antigen 106 30 (28.3) 9/17 1 and 7A/F (n = 4 each), 19A
a N, number of isolates assayed for serotype identiﬁcation.
b NT, non-typeable.
c Collected via endotracheal tube or bronchoalveolar lavage.
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PCV7 serotypes were either unvaccinated (n=9) or PCV7-vaccinated
(n = 12).
Pneumococcal urinary antigen was not detected in any of the 40
children with nasopharyngeal pneumococcal carriage only (on
culture and/or PCR) and no evidence of likely pneumococcal
infection. Half (15/30) of those with Binax-positive samples also
had S. pneumoniae identiﬁed in a sterile site. Of the 17 Binax-positive
urines tested, nine identiﬁed pneumococcal serotypes. Four of these
had concordant identiﬁcation of same serotypes from pleural ﬂuid (2
were serotype 1, one each of serotypes 7A/F and 19A).
4. Discussion
This study provides the ﬁrst information on serotype distribution
of pneumococcal PCAP in the UK after the routine introduction of the
pneumococcal conjugate vaccine. Its timing towards the end of 3
years of PCV7 and during the ﬁrst year of PCV13 gives an opportunity
for future evaluation of the aetiology of pneumonia in the same
setting. Non-PCV7 but PCV13 serotypes were the major contributor to
the aetiology of CAP.
We detected likely pneumococcal infection in 26% of children with
PCAP, more than previously described in the UK (Clements et al.,
2000; Drummond et al., 2000). With no association between urinary
pneumococcal antigen and nasopharyngeal pneumococcal carriage in
this study, urinary pneumococcal antigen is likely to indicate a
pathogen than carriage. Diagnosis of pneumococcal infection was
increased considerably when pneumolysin PCR was used (Esposito et
al., 2012; Strachan et al., 2012), improving the detection rate from 6%
by culture alone to 23%. This is similar to the increase (3.8% to 15.4%)
reported in a recent Italian study (Resti et al., 2010). It has recently
been recognised that the pneumolysin gene can be detected in non-
pneumococcal Viridans-group streptococci, particularly S. pseudop-
neumoniae and S. mitis (Carvalho Mda et al., 2007), thus introducing
the possibility of false positivity with pneumococcal PCR. We feel this
is unlikely given the clinical context; serotype identiﬁcation would
not be affected.
In England and Wales non-PCV7 serotypes are now associated
with invasive pneumococcal disease (Miller et al., 2011), and an
increase in pneumococcal serotype 19A is associated with complicat-
ed pneumonia with empyema (Thomas et al., 2012). The observed
increase in detection of pneumococci in this study is presumably
related to both improved molecular techniques and continued
pneumococcal disease due to replacement with non-PCV7 serotypes.
Although the number of serotyped pneumococcal isolates was low,
with the majority being identiﬁed from pleural ﬂuids, none were
covered in PCV7, but are included in PCV13. This is reﬂected by datafrom the USA on children with empyema, where 98% were non-
PCV7 serotypes (Byington et al., 2010). This suggests that PCV13
could substantially reduce invasive pneumococcal disease (Jefferies
et al., 2011).
In conclusion, non-PCV7 serotypes were the major contributor to
the aetiology of pneumococcal pneumonia in UK children. Continued
surveillance is required to monitor for the emergence of serotype
replacement.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.diagmicrobio.2013.02.012.
Acknowledgments
We thank the research nurses; Kerry Pollard, Pauline Singleton and
Clare Simmister for their assistance with data collection. We are
indebted to Dr Michelle Muller, Consultant Cardiothoracic Radiologist
for reviewing the chest radiographs; Audrey Nicholson for laboratory
support at the Department of Microbiology, Freeman Hospital
Newcastle; and Dr Robert George and Carmen Sheppard for running
the xMAP immunoassay for serotyping the pneumococcal isolates in
the national Respiratory and Systemic Infection Laboratory at the
Health Protection Agency in London.
References
Brent AJ, Ahmed I, Ndiritu M, Lewa P, Ngetsa C, Lowe B, et al. Incidence of clinically
signiﬁcant bacteraemia in children who present to hospital in Kenya: community-
based observational study. Lancet 2006;367:482–8.
Byington CL, Hulten KG, Ampofo K, Sheng X, Pavia AT, Blaschke AJ, et al. Molecular
epidemiology of pediatric pneumococcal empyema from 2001 to 2007 in Utah. J
Clin Microbiol 2010;48:520–5.
Carvalho Mda G, Tondella ML, McCaustland K, Weidlich L, McGee L, Mayer LW, et al.
Evaluation and improvement of real-time PCR assays targeting lytA, ply, and psaA
genes for detection of pneumococcal DNA. J Clin Microbiol 2007;45:2460–6.
Charkaluk ML, Kalach N, Mvogo H, Dehecq E, Magentie H, Raymond J, et al. Assessment
of a rapid urinary antigen detection by an immunochromatographic test for
diagnosis of pneumococcal infection in children. Diagn Microbiol Infect Dis
2006;55:89–94.
Cherian T, Mulholland EK, Carlin JB, Ostensen H, Amin R, de Campo M, et al.
Standardized interpretation of paediatric chest radiographs for the diagnosis of
pneumonia in epidemiological studies. Bull World Health Organ 2005;83:353–9.
Clements H, Stephenson T, Gabriel V, Harrison T, Millar M, Smyth A, et al. Rationalised
prescribing for community acquired pneumonia: a closed loop audit. Arch Dis Child
2000;83:320–4.
Corless CE, Guiver M, Borrow R, Edwards-Jones V, Fox AJ, Kaczmarski EB. Simultaneous
detection of Neisseria meningitidis, Haemophilus inﬂuenzae, and Streptococcus
pneumoniae in suspected cases of meningitis and septicemia using real-time PCR.
J Clin Microbiol 2001;39:1553–8.
Drummond P, Clark J, Wheeler J, Galloway A, Freeman R, Cant A. Community acquired
pneumonia — a prospective UK study. Arch Dis Child 2000;83:408–12.
Esposito S, Marchese A, Tozzi AE, Rossi GA, Dalt LD, Bona G, et al. Bacteremic
pneumococcal community-acquired pneumonia in children less than 5 years of age
in Italy. Pediatr Infect Dis J 2012;31:705–10.
132 M.A. Elemraid et al. / Diagnostic Microbiology and Infectious Disease 76 (2013) 129–132Hamer DH, Egas J, Estrella B, MacLeod WB, Grifﬁths JK, Sempertegui F. Assessment of
the Binax NOW Streptococcus pneumoniae urinary antigen test in children with
nasopharyngeal pneumococcal carriage. Clin Infect Dis 2002;34:1025–8.
Jefferies JM, Macdonald E, Faust SN, Clarke SC. 13-Valent pneumococcal conjugate
vaccine (PCV13). Hum Vaccin 2011;7:1012–8.
Korppi M, Leinonen M, Ruuskanen O. Pneumococcal serology in children's respiratory
infections. Eur J Clin Microbiol Infect Dis 2008;27:167–75.
Miller E, Andrews NJ, Waight PA, Slack MP, George RC. Herd immunity and serotype
replacement 4 years after seven-valent pneumococcal conjugate vaccination in
England and Wales: an observational cohort study. Lancet Infect Dis 2011;11:
760–8.
Resti M,MoriondoM, Cortimiglia M, Indolﬁ G, Canessa C, Becciolini L, et al. Community-
acquired bacteremic pneumococcal pneumonia in children: diagnosis and
serotyping by real-time polymerase chain reaction using blood samples. Clin Infect
Dis 2010;51:1042–9.Rudan I, Boschi-Pinto C, Biloglav Z, Mulholland K, Campbell H. Epidemiology and
etiology of childhood pneumonia. Bull World Health Organ 2008;86:408–16.
Sheppard CL, Harrison TG, Smith MD, George RC. Development of a sensitive,
multiplexed immunoassay using xMAP beads for detection of serotype-speciﬁc
Streptococcus pneumoniae antigen in urine samples. J Med Microbiol 2011;60:
49–55.
Strachan RE, Cornelius A, Gilbert GL, Gulliver T, Martin A, McDonald T, et al. Pleural ﬂuid
nucleic acid testing enhances pneumococcal surveillance in children. Respirology
2012;17:114–9.
Thomas MF, Sheppard CL, Guiver M, Slack MP, George RC, Gorton R, et al. Emergence of
pneumococcal 19A empyema in UK children. Arch Dis Child 2012;97:1070–2.
Turner P, Hinds J, Turner C, Jankhot A, Gould K, Bentley SD, et al. Improved detection of
nasopharyngeal cocolonization bymultiple pneumococcal serotypes by use of latex
agglutination or molecular serotyping by microarray. J Clin Microbiol 2011;49:
1784–9.
